Coronavirus Disease 2019–Associated Pulmonary Aspergillosis in Mechanically Ventilated Patients
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: Coronavirus disease 2019 (COVID-19)–associated pulmonary aspergillosis (CAPA) occurs in critically ill patients with COVID-19. Risks and outcomes remain poorly understood. Methods: A retrospective cohort study of mechanically ventilated adult patients with COVID-19 admitted to 5 Johns Hopkins hospitals was conducted between March and August 2020. CAPA was defined using composite clinical criteria. Fine and Gray competing risks regression was used to analyze clinical outcomes and, multilevel mixed-effects ordinal logistic regression was used to compare longitudinal disease severity scores. Results: In the cohort of 396 people, 39 met criteria for CAPA. Patients with CAPA were more likely than those without CAPA to have underlying pulmonary vascular disease (41% vs 21.6%, respectively; P = .01), liver disease (35.9% vs 18.2%; P = .02), coagulopathy (51.3% vs 33.1%; P = .03), solid tumors (25.6% vs 10.9%; P = .02), multiple myeloma (5.1% vs 0.3%; P = .03), and corticosteroid exposure during the index admission (66.7% vs 42.6%; P = .005), and had lower body mass indexes (median, 26.6 vs 29.9 [calculated as weight in kilograms divided by height in meters squared]; P = .04). Patients with CAPA had worse outcomes, as measured by ordinal severity of disease scores, requiring longer time to improvement (adjusted odds ratio, 1.081.091.1; P < .001), and advancing in severity almost twice as quickly (subhazard ratio, 1.31.82.5; P < .001). They were intubated twice as long as those without CAPA (subhazard ratio, 0.40.50.6; P < .001) and had longer hospital stays (median [interquartile range], 41.1 [20.5–72.4) vs 18.5 [10.7–31.8] days; P < .001). Conclusion: CAPA is associated with poor outcomes. Attention to preventive measures (screening and/or prophylaxis) is warranted in people with high risk of CAPA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254
Factors associated with COVID-19-related death using OpenSAFELY
Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., Curtis, H. J., Mehrkar, A., Evans, D., Inglesby, P., et al. (2020) · Nature · doi:10.1038/s41586-020-2521-4 · Cited by 6,674
Schauwvlieghe, A. F. A. D., Rijnders, B. J. A., Philips, N., Verwijs, R., Vanderbeke, L., Van Tienen, C., Lagrou, K., Verweij, P. E., Van de Veerdonk, F. L., Gommers, D., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30274-1 · Cited by 886
COVID-19 Associated Pulmonary Aspergillosis
Koehler, P., Cornely, O. A., Böttiger, B. W., Dusse, F., Eichenauer, D. A., Fuchs, F., Hallek, M., Jung, N., Klein, F., Persigehl, T., et al. (2020) · Mycoses · doi:10.1111/myc.13096 · Cited by 547 · cited 4×
“0, or positive culture for Aspergillus species in BAL.[4,5,7] As our institution relies on FDA-cleared cut-offs for positive BAL GM at index >0.”
InfluentialAspergillosis Complicating Severe Coronavirus Disease
Marr, K. A., Platt, A., Tornheim, J. A., Zhang, S. X., Datta, K., Cardozo, C., & Garcia-Vidal, C. (2021) · Emerging Infectious Diseases · doi:10.3201/eid2701.202896 · Cited by 190
Self-citation
Cited by
COVID-19-associated fungal infections
Hoenigl, M., Seidel, D., Sprute, R., Cunha, C., Oliverio, M., Goldman, G. H., Ibrahim, A. S., & Carvalho, A. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01172-2 · Cited by 482
Prattes, J., Wauters, J., Giacobbe, D. R., Salmanton-García, J., Maertens, J., Bourgeois, M., Reynders, M., Rutsaert, L., Van Regenmortel, N., Lormans, P., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.08.014 · Cited by 233
“Indeed, the majority of patients with severe COVID-19 in this study received systemic corticosteroids, which is in contrast to some of the earlier studies where use of systemic corticosteroids was less frequent [6,7,29].”
Mortality Trends in Risk Conditions and Invasive Mycotic Disease in the United States, 1999–2018
Rayens, E., Norris, K. A., & Cordero, J. F. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab336 · Cited by 63
Hoenigl, M., Egger, M., Price, J., Krause, R., Prattes, J., & White, P. L. (2023) · Journal of Clinical Microbiology · doi:10.1128/jcm.01859-22 · Cited by 51
Metadata
- Authors
- Permpalung, N., Chiang, T. P.-Y., Massie, A. B., Zhang, S. X., Avery, R. K., Nematollahi, S., Ostrander, D., Segev, D. L., & Marr, K. A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-03-09
- Volume
- 74
- Issue
- 1
- Pages
- 83-91
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W3135203342
- Cited by
- 103
- References
- 5
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Coronavirus Disease 2019–Associated Pulmonary Aspergillosis in Mechanically Ventilated Patients. https://app.cochat.ai/papers/10.1093/cid/ciab223
- The paper
- Permpalung, N., Chiang, T. P.-Y., Massie, A. B., Zhang, S. X., Avery, R. K., Nematollahi, S., Ostrander, D., Segev, D. L., & Marr, K. A. (2022). Coronavirus Disease 2019–Associated Pulmonary Aspergillosis in Mechanically Ventilated Patients. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciab223
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.